What Мидиана Treats: Main Uses and Benefits

The primary purpose of this agent, traditionally known as Damiana, is to offer supportive relief across several key symptomatic domains, aiming to improve general well-being and daily comfort. It has been historically used as a stimulant, aphrodisiac, and nerve tonic. It is commonly used across conditions presenting with episodic or fluctuating manifestations such as mild sexual dysfunction, symptoms of general nervousness, stress, and physical fatigue.

The support offered is relevant when symptoms become temporarily overwhelming and interfere with daily functioning. The focus is on providing supportive relief that may assist with managing the overall symptom burden, helping patients cope with distress and temporary discomforts. It is also relevant in clinical settings where supportive symptom management is appropriate, such as for minor digestive complaints like occasional constipation.

Quick Fact: Relief for Nervous Tension and Mild Sexual Dysfunction

“It may assist with maintaining a sense of stability when symptoms are more noticeable, contributing to easing the overall symptom load during difficult episodes.”

Eligibility Map: Who can and cannot use Мидиана — official regulatory information

The official eligibility profile for Мидиана is defined by regulatory documents, which establish strict rules for use based on health status and age.

Eligibility Scope

Populations for whom use is allowed: Use is officially allowed for women of reproductive age who have reached menarche (onset of menstruation). The medicine is not indicated for post-menopausal women.

Populations for whom use is contraindicated: Use is strictly prohibited for females with a known history of thrombotic events (such as DVT, PE, stroke, or MI), and those with current or history of sex-steroid-sensitive cancers (like breast cancer) or liver tumors. Pregnancy is an absolute contraindication.

Condition-specific eligibility rules

The medicine is contraindicated for patients with severe pre-existing conditions, including severe hepatic or renal impairment, adrenal insufficiency, uncontrolled hypertension, or diabetes with vascular involvement. The medicine is generally not recommended during lactation.

Eligibility-related restrictions

Use is prohibited for women who smoke and are over 35 years old. Furthermore, the official label requires use to be temporarily suspended around major surgery (four weeks before and two weeks after) and delayed until at least four weeks post-partum to manage the risk of thrombosis.

Connection to the overall eligibility profile

Official regulatory documents strictly define who can and cannot use Мидиана by establishing absolute contraindications based primarily on vascular, oncologic, and organ function status. Eligibility is limited to women of reproductive age who meet specific health criteria, while use is formally prohibited during pregnancy and in women with defined high-risk comorbidities.

Interaction Map: Interactions with other medicines and products — official regulatory information for Мидиана

Interaction Scope

Category	Official Regulatory Documentation Summary
Medicinal product categories with documented interactions	Strong CYP3A4 inhibitors and inducers, select Hepatitis C virus (HCV) combination products, Potassium-sparing diuretics, ACE Inhibitors, Angiotensin-II Receptor Blockers (ARBs), and Thyroid hormone replacement therapies.
Specific interacting medicines (if explicitly listed)	Ombitasvir / Paritaprevir / Ritonavir, Glecaprevir / Pibrentasvir, Rifampin, Carbamazepine, Phenytoin, Ketoconazole, Itraconazole, Lamotrigine, and St. John's Wort.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic: Inhibition or induction of CYP3A4 enzyme, leading to altered plasma concentrations. Pharmacodynamic: Additive effect on serum potassium levels due to Drospirenone's anti-mineralocorticoid activity. Protein Binding Alteration: Increase in serum concentrations of thyroid-binding globulin (TBG).
Timing-based interaction rules (if applicable)	No mandatory, specified timing-based separation requirements are documented in primary regulatory labels for the listed interactions.
Population-specific interaction notes (if applicable)	The risk of Hyperkalemia is specifically heightened in females with Renal Impairment or Adrenal Insufficiency when co-administering with other potassium-elevating drugs.
Interaction-related restrictions	Co-administration is prohibited with the combination products containing Ombitasvir / Paritaprevir / Ritonavir (with or without Dasabuvir) or Glecaprevir / Pibrentasvir.

---

Interaction Classifications (High-Level)

Classification Type	Summary as Defined in Official Documents
Interaction severity classification (as defined in official documents)	Contraindicated: Select HCV combination products. Clinically Significant: Interactions resulting in decreased contraceptive effectiveness or risk of hyperkalemia. Impact on Concomitant Therapy: Interactions necessitating consideration for adjusting co-administered drug dosage.
Regulatory basis (EMA / FDA / etc.)	Based on official governmental regulatory documents, including FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).
Interaction-context constraints (as defined in official documents)	Mandatory serum potassium monitoring is required during the first treatment cycle when Мидиана is co-administered with drugs known to increase potassium in high-risk females.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with select Hepatitis C antiviral combinations is contraindicated due to the documented risk of liver enzyme elevations.
• CYP3A4 inducers, including St. John's Wort, are documented to decrease the plasma concentration of contraceptive components, which may reduce efficacy.
• The combination with potassium-elevating agents (e.g., Spironolactone, ACE Inhibitors) is documented to carry a risk of hyperkalemia due to Drospirenone’s unique anti-mineralocorticoid activity.
• Ethinyl Estradiol's effect on thyroid-binding globulin may necessitate an adjustment in the dose of thyroid hormone replacement therapy.

Connection to the overall interaction profile (3 sentences): Official regulatory documents define the product’s interaction structure primarily around the formal prohibition of co-administration with select antiviral combinations and the pharmacodynamic risk of hyperkalemia with potassium-elevating agents. The profile further mandates the consideration of pharmacokinetic interference via CYP3A4 enzyme induction or inhibition, which formally modifies the exposure and potential efficacy of the product. These documented interactions necessitate procedural constraints, such as mandatory potassium monitoring in specific patient populations, as stated in the prescribing information.

Мидиана is a combination of two synthetic steroids: drospirenone and ethinylestradiol.

Ethinylestradiol provides an estrogenic component that acts on the liver to increase the synthesis of Sex Hormone-Binding Globulin (SHBG). This systemic increase in SHBG reduces the circulating concentration of free androgens.

Drospirenone functions as an agonist at the progesterone receptor (PR) and as an antagonist at both the mineralocorticoid receptor (MR) and the androgen receptor (AR).

In the hypothalamic-pituitary-ovarian axis, the combined action of both components exerts a negative feedback on the pituitary gland. This suppression inhibits the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), leading to a profound suppression of follicular development and inhibition of ovulation.

Peripherally, drospirenone's PR agonism alters the cervical mucus viscosity and induces premature secretory changes in the endometrium. Its MR antagonism blocks the action of aldosterone in the renal distal tubules, promoting natriuresis and diuresis. The AR antagonism counteracts the binding of endogenous androgens to their respective receptors in target tissues.

How to Use Мидиана

Мидиана is administered exclusively via the oral route as a film-coated tablet containing the active synthetic hormones Drospirenone and Ethinyl Estradiol. The dosing regimen is cyclic, rather than continuous, and is governed by a standard 28-day course, which commonly follows a 21 active tablet/7 inactive day schedule or a 24 active tablet/4 inert day schedule.

The usage protocol mandates taking one tablet daily at approximately the same time, maintaining a consistent 24-hour interval between doses. Adherence to the specific sequence indicated on the packaging is required for proper administration. The tablets may be taken with or without food.

Administration starts using a Day 1 Start or a Sunday Start protocol. If initiation occurs later than the first day of the menstrual cycle, a non-hormonal back-up method must be used for the first seven consecutive days of the regimen. Procedural instructions for managing gastrointestinal issues require taking a replacement active tablet if vomiting or severe diarrhea occurs within 3–4 hours of dosing. Official labeling explicitly contraindicates its use in patients with pre-existing hepatic or renal impairment.

This usage structure defines a standardized approach to medication intake that is reliant on daily precision and adherence to the 28-day cycle framework.

Research Evidence / Overview of Studies for Мидиана

---

Evidence for Use in Preventing Pregnancy (Contraception)

The combination of Drospirenone and Ethinyl Estradiol was studied to assess outcomes related to conception prevention. This research is based on a foundation of large-scale, open-label, multicenter Randomized Controlled Trials (RCTs) and subsequent extensive Post-marketing Observational Studies that track use patterns. Studies monitored two main outcomes: the pregnancy rate, calculated using metrics like the Pearl Index, and the rate at which participants continued using the medication throughout the study period. The documented pregnancy rates contribute to the broader evidence landscape regarding conception prevention.

However, the calculation of the pregnancy rate may vary significantly based on whether participants adhere perfectly to the dosing schedule or follow a more typical use pattern. While the evidence base is extensive, there is limited information for long-term outcomes when trying to compare it directly against every other type of hormonal contraceptive available.

---

Evidence for Use in Premenstrual Dysphoric Disorder (PMDD) and Moderate Acne Vulgaris

Research examined the specific combination to evaluate outcomes related to PMDD symptoms in rigorous, double-blind, placebo-controlled trials. Studies monitored patient-reported outcomes describing perceived discomfort related to mood fluctuations, anxiety, and physical distress using validated scales. The research also explored outcomes related to moderate acne vulgaris in separate, placebo-controlled studies, examining specific outcomes such as acne lesion counts and standardized skin appearance scores.

In both indications, a key limitation is the limited follow-up duration of the core controlled trials. For PMDD, trials typically covered only three menstrual cycles, and for acne, approximately six months. As a result, long-term effects are not fully established regarding how symptoms may evolve beyond the initial short-term study period. Furthermore, comparative evidence is lacking in terms of dedicated, head-to-head trials against other similar compounds.

Key Studies & References

1. Drospirenone/ethinyl estradiol. - Clinical Pharmacology and Therapeutics review
2. A Combined Oral Contraceptive Containing 3-mg Drospirenone/ 20-µg Ethinyl Estradiol in the Treatment of Acne Vulgaris: A Randomized Controlled Trial
3. Public Assessment Reports of the Medicines Evaluation Board in the Netherlands: Ethinylestradiol/Drospirenon 24+4 0.02 mg/3 mg (MEB)

Common questions about Мидиана (FAQ)

---

Q: How quickly can Мидиана start working, generally speaking?

Official regulatory documents indicate that the body requires a period of adjustment before contraceptive protection is established. It takes at least seven consecutive days of tablet-taking for the mechanism to be fully in effect. Regulatory information indicates that a non-hormonal back-up method may be advised for the first seven days of the first pill cycle.

---

Q: What are the most commonly reported side effects listed in the documents?

According to the official product information, the most commonly documented adverse reactions include headache, nausea, breast pain or tenderness, and irregular menstrual periods. These effects are generally classified as common, meaning they may affect between 1 in 100 and 1 in 10 users.

---

Q: Are headaches a common concern for users of Мидиана?

Official documentation classifies headache as a common adverse reaction associated with this medication. While headaches may occur, migraines are classified as an uncommon side effect. Regulatory sources also note that migraine with focal neurological symptoms is an absolute contraindication for use.

---

Q: Why do official documents emphasize the risk of blood clots with this type of medicine?

The emphasis is based on the documented, serious risk of venous and arterial thromboembolic events (VTE/ATE), such as blood clots. This risk is primarily associated with the estrogen component of combined oral contraceptives. Official documents strictly define who can and cannot use the medication based on this risk profile.

---

Q: Is it necessary to have a medical check-up before starting Мидиана?

The regulatory profile of the drug includes numerous contraindications and defined health risk factors. A healthcare professional is necessary to assess an individual's specific health status to determine eligibility for use.

---

Q: Does alcohol interact with Мидиана?

Specific clinical interactions between this medication and alcohol are not detailed as a contraindication or clinically significant interaction in the main regulatory documents. Official information sometimes includes general advice regarding the use of food, alcohol, or tobacco.

---

Q: Does Мидиана affect mood or weight according to official descriptions?

Official safety profiles list increased weight and mood changes (such as depression) as documented adverse reactions reported in clinical studies. The full regulatory safety information contains further details.

---

Q: Is it true that Мидиана can interact with herbal supplements?

Official regulatory documents explicitly state that the herbal supplement St. John’s Wort is known to interact with the medication. This interaction is mediated by liver enzymes and may lead to a reduction in the drug's effectiveness.

---

Q: Can antibiotics reduce the effect of Мидиана?

Regulatory information indicates that only a specific class of antibiotics known as rifamycins (e.g., Rifampin) can significantly reduce the drug's effectiveness due to their documented effect on liver enzyme induction. For most other common antibiotics, a clinically significant interaction is not documented.

---

Q: Are there any specific age limits mentioned for Мидиана use?

The medicine is indicated for females of reproductive potential. For certain secondary indications like acne, official use may be specified for women at least 14 years of age. Official use is prohibited for women who smoke and are over 35 years old, as documented in the contraindications.

---

Q: What is the key difference between Мидиана and similar combination drugs?

The main differentiating factor of the active ingredient Drospirenone is its documented anti-mineralocorticoid activity. This unique property is associated with an effect on the body’s fluid balance and potassium levels, as described in the pharmacodynamics.

---

Q: Can Мидиана be used by people with a history of migraines?

Use is officially contraindicated in patients with a history of migraine with focal neurological symptoms. The presence of any migraine should be noted, as is generally required for the assessment of risks by a healthcare professional.

---

Q: Is there information available on long-term safety studies for Мидиана?

Official regulatory overviews confirm that post-marketing surveillance is ongoing for the product. However, they also state that the long-term effects beyond the initial, shorter-duration core clinical trials for some indications (like PMDD and acne) are not fully established.

---

Q: How does the official research describe the success rate of Мидиана?

Official research assesses contraceptive effectiveness using the Pearl Index (PI). This metric calculates the number of pregnancies that occur per 100 women during one year of use. The reported rate depends on whether the medication is used perfectly or typically.

---

Q: Is it normal to have spotting when first starting Мидиана?

Official documents list spotting and irregular uterine bleeding as common adverse reactions. These effects are particularly noted during the initial months of starting the medication, as the body adjusts to the hormonal components.

---

Q: What if I forget to take a pill, what does the official leaflet suggest I do?

The official product leaflet provides specific instructions for a missed dose. These instructions are dependent on the time delay and the week in the cycle the pill was missed. The patient information details the required actions, which may include using a back-up barrier method.

---

Q: Does Мидиана have a dedicated page on the FDA or EMA website?

Yes, authoritative public documentation for the active ingredients in Мидиана is available online. The FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC) are located on their respective government public databases.

---

Q: Is there any research about Мидиана's effect on skin?

Official research has specifically examined outcomes related to moderate acne vulgaris as a studied secondary indication for this combination of active ingredients. The studies evaluate the medication's effect on acne lesion counts and overall skin appearance.

---

Q: What are the signs of a serious, but rare, side effect described in the safety information?

The official safety information describes symptoms of serious, rare side effects like blood clots (VTE). These symptoms may include swelling, tenderness, and pain in the leg, or sharp chest pain and breathlessness. This information is provided in the official warnings for patient awareness.

---

Q: Does being overweight change who can use Мидиана?

Regulatory data indicates that being overweight is listed as a risk factor that can increase the risk of blood clots (VTE). Additionally, some research suggests that contraceptive effectiveness may be lower in women with a higher Body Mass Index (BMI).

---

Q: Do studies exist that compare Мидиана to placebo?

Official research confirms that placebo-controlled studies were conducted for the secondary indications of Premenstrual Dysphoric Disorder (PMDD) and moderate acne vulgaris. These studies were used to establish the evidence base for these specific uses.

---

Q: Can this medication affect the results of blood tests?

The estrogen component in the medication can affect the concentration of certain binding proteins in the blood. Because of this, the medication may influence the results of some laboratory blood tests, and this potential effect is documented in the official prescribing information.

---

Q: Are there different strengths of Мидиана available?

The specific pharmaceutical product Мидиана is officially listed in regulatory documents with a single dosage strength. This strength consists of 3 mg of Drospirenone and 0.03 mg of Ethinyl Estradiol in each active tablet.

How to Store and Dispose of Midiana

The storage and handling of Midiana (drospirenone and ethinylestradiol) must adhere strictly to the conditions specified in regulatory labeling to maintain product stability and safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store at a temperature below 30 C.
Protection	Store in the original package to protect from light.
Safety	Keep this medicine out of the sight and reach of children (Child safety requirement).

Disposal Instructions

Unused or expired Midiana must be disposed of in a manner that protects the environment. Regulatory requirements state that the product should not be thrown into wastewater or household waste. Disposal must be carried out in accordance with local requirements for pharmaceutical waste.